Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicostop
- Development stage
- Unknown
- Lead developer
- Laboratoires Lehning
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nicostop is a non-specific product name used for more than one smoking-cessation product rather than a single well-defined drug. In the provided context, it refers at least to a nicotine-containing smoking-cessation pharmaceutical marketed as Nicostop-Mepha for relief of nicotine withdrawal and cigarette dependence, and separately to a French homeopathic tablet product containing lycopodium, staphysagria, lobelia, and tobaccum that is promoted for reducing tobacco craving. Because these products differ in active ingredients, mechanism, developer, and regulatory character, Nicostop should be treated as an ambiguous name unless a manufacturer or formulation is specified.
- Brand names
- NicostopNicostop-Mepha
- Other names
- Nicostop Tablets
Beyond the preview
Go deeper on Nicostop.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nicostop.